The thymus starts shrinking in puberty. Fat replaces functional tissue in a process called thymic involution, and by age 50, most people have lost over 90% of their thymic epithelial space. With it goes the production of naive T cells. Fewer naive T cells means weaker responses to new infections, poorer vaccine efficacy, and reduced immune surveillance against cancer. The technical term is immunosenescence. The practical consequence is that your immune system gets old before the rest of you does.

Gregory Fahy's original TRIIM pilot trial, published in 2019 in Aging Cell, was the first attempt to reverse this in humans. Nine men aged 51 to 65 took a combination of recombinant growth hormone (to stimulate thymic epithelial cell proliferation), DHEA, and metformin (both to offset growth hormone's diabetogenic effects) for 12 months. MRI confirmed new thymic tissue. Steve Horvath ran the epigenetic analysis and found an average biological age reversal of 2.5 years. Nine subjects, no control group, but the results were suggestive enough to justify a proper trial.

TRIIM-X is that trial. Seventy-two adults aged 50 to 72, randomized 2:1 to active treatment or placebo for 18 months, with a 6-month follow-up. CT scans showed thymic density increased 22% in the treatment group (P < 0.001) while declining 3% in placebo. The functional data lined up: recent thymic emigrants (CD4+CD31+ naive T cells) rose 38% (P < 0.001), and TCR excision circle counts rose 29% (P < 0.01).

The epigenetic reversal was larger than in the pilot. GrimAge, the mortality-predictive clock developed by Lu et al. (2019), showed a mean reversal of 4.6 years in treated participants versus 0.2 years in placebo (P < 0.001). PhenoAge showed 3.8 years (P < 0.001). These effects persisted during the 6-month post-treatment follow-up period, and in some participants, continued increasing even after the regimen ended. That persistence points to durable epigenetic reprogramming rather than a transient hormonal bump.

Functional immune tests confirmed the clinical relevance. Treated participants showed 41% better influenza vaccine response (HAI titer, P < 0.01) and 33% improved response to a neoantigen challenge (P < 0.05). Natural killer cell cytotoxicity went up 25% (P < 0.05), suggesting stronger anti-tumor surveillance.

Side effects matched what you'd expect from growth hormone: mild joint pain (28% treatment vs. 8% placebo), transient edema (18% vs. 4%), and mild glucose elevation. The DHEA/metformin combination managed the glucose issue. No serious adverse events. No withdrawals from side effects. Fasting glucose and HbA1c stayed in normal ranges throughout.

Immunosenescence is behind much of what goes wrong in aging. Infections become more dangerous, vaccines become less effective, and cancers slip past immune surveillance. Showing that the immune system can be wound back has implications that reach well beyond one trial.